EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Results from a Phase 1 Study Assessing the Pharmacokinetics of the Aldosterone Synthase Inhibitor Baxdrostat in Participants with Varying Degrees of Renal Function

Mason W Freeman, Yuan-Di Halvorsen, Mary Bond, Brian Murphy, Jonathan Isaacsohn

Clinical Pharmacology in Drug Development · 2024-04 · 13 (4) · 410-418

DOI: 10.1002/cpdd.1371 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 04.02.2024. Verfasst von Mason W Freeman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Computational and Integrative Biology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Renal Insufficiency, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Baxdrostat is a selective small‐molecule aldosterone synthase inhibitor in development for treatment of hypertension and chronic kidney disease. This phase 1, open‐label, parallel‐group study assessed the safety and pharmacokinetics (PK) of baxdrostat in participants with varying degrees of renal function. Participants were enrolled into control (estimated glomerular filtration rate [eGFR] ≥60 mL/min), moderate to severe renal impairment (eGFR 15‐59 mL/min), or kidney failure (eGFR

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal InsufficiencyRenal Insufficiency, ChronicHumansCytochrome P-450 CYP11B2Glomerular Filtration RateKidney

Stichwörter der Autor:innen

CYP11B2aldosterone synthase inhibitorbaxdrostatchronic kidney diseaserenal impairment

Substanzen

Cytochrome P-450 CYP11B2

Autor:innen und Institutionen

  • Center for Computational and Integrative Biology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • CinCor Pharma, Inc., Waltham, MA, USA.
  • CinRx Pharma, LLC, Cincinnati, OH, USA.

Zitieren

APA

Freeman, M. W., Halvorsen, Y. D., Bond, M., Murphy, B., & Isaacsohn, J. (2024). Results from a Phase 1 Study Assessing the Pharmacokinetics of the Aldosterone Synthase Inhibitor Baxdrostat in Participants with Varying Degrees of Renal Function. Clinical Pharmacology in Drug Development, 13(4), 410-418. https://doi.org/10.1002/cpdd.1371

Vancouver

Freeman MW, Halvorsen YD, Bond M, Murphy B, Isaacsohn J. Results from a Phase 1 Study Assessing the Pharmacokinetics of the Aldosterone Synthase Inhibitor Baxdrostat in Participants with Varying Degrees of Renal Function. Clinical Pharmacology in Drug Development. 2024;13(4):410-418. doi:10.1002/cpdd.1371

BibTeX
@article{Freeman2024,
  author = {Freeman, Mason W and Halvorsen, Yuan-Di and Bond, Mary and Murphy, Brian and Isaacsohn, Jonathan},
  title = {Results from a Phase 1 Study Assessing the Pharmacokinetics of the Aldosterone Synthase Inhibitor Baxdrostat in Participants with Varying Degrees of Renal Function},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2024},
  volume = {13},
  number = {4},
  pages = {410--418},
  doi = {10.1002/cpdd.1371}
}
Kostenlos starten →